Statistics for Perspective Therapeutics, Common Stock (id:170 CATX)
Valuation metrics
Market cap
270,35M
Enterprise value
6,77M
Trailing P/E (ttm)
-2,06
Forward P/E
-3,70
PEG ratio
-3,70
Price/Sales (ttm)
173,64
Price/Book (mrq)
3,00
Enterprise Value/Revenue
4,35
Enterprise Value/EBITDA
3,00
Overview
Shares outstanding
67,59M
Float
43,46M
Shares short
8,28M
% Held by insiders
3,00%
% Held by institutions
3,00%
Average volume (10 days)
4,13M
Average volume (90 days)
Price summary
52-Week low
2,70
52-Week high
19,10
52-Week change
-62,86%
Beta
1,47
50-Day moving average
10,60
200-Day moving average
12,63
Dividends and splits
Forward annual dividend rate
Forward annual dividend yield
Trailing annual dividend rate
0,00%
Trailing annual dividend yield
0,00
5-Year annual dividend yield
Payout ratio
0,00
Dividend date
Ex-dividend date
Last split factor
2:1
Last split date
June 17, 2024
Financials
Fiscal yearFiscal year ends
December 31, 2023
Most recent quarter (mrq)
September 30, 2024
Profitability
Profit margin
0,00%
Operating margin
-5.049,86%
Operational effectiveness
Return on assets
-14,35%
Return on equity
-27,02%
Income statement
Revenue (ttm)
5,00
Revenue per share (ttm)
5,00
Quarterly revenue growth (yoy)
Gross profit (ttm)
0,00
EBITDA
-55.762.000,00
Net income to common (ttm)
-57.712.000,00
Diluted EPS (ttm)
-1,33
Quarterly earnings growth (yoy)
Balance sheet
Total cash (mrq)
267,85M
Total cash per share (mrq)
3,96
Total debt (mrq)
4,27M
Total Debt/Equity (mrq)
1,30
Current ratio (mrq)
960,00%
Book value per share (mrq)
4,86
Cash flow
Cash flow statement
-696.000,00
Levered free cash flow (LFCF)
-49.486.876,00